CoChat

CHARACTERIZATION OF STERILE INTRAOCULAR INFLAMMATORY RESPONSES AFTER INTRAVITREAL BEVACIZUMAB INJECTION

The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.

Abstract

PURPOSE: The purpose of this study was to determine the frequency and characteristics of sterile intraocular inflammation occurring after intravitreal bevacizumab (IVB) (Avastin, Genentech, South San Francisco, CA) injection and to analyze whether a repeat IVB or intravitreal ranibizumab (IVR) (Lucentis, Genentech) injection after an episode of postinjection inflammation elicits a repeat inflammatory reaction. METHODS: A retrospective case series evaluated 16,166 IVB injections administered between 2006 and 2008. Patients with postinjection inflammation were analyzed for the number of previous injections, time from prior injection to incident injection, presenting signs and symptoms, treatment, visual acuity, time from onset to resolution and recovery of vision, and whether repeat injection caused recurrent inflammation. RESULTS: The incidence of sterile intraocular inflammation after IVB injection resolving with topical antibiotics and steroids alone was 0.27% (44 of 16,166). The average number of prior IVB injections in the ipsilateral eye was 2.8 ± 0.4 with 10 cases occurring with first-time injections. The average time from injection to recovery of visual acuity was 53 ± 18 days, and from injection to resolution of inflammation was 37 ± 5 days. Thirty-six cases received subsequent IVB or intravitreal ranibizumab, and there were three episodes of recurrent inflammation with repeat IVB. The average follow-up was 17 ± 1 month. CONCLUSION: In most cases of sterile intraocular inflammation after IVB, visual acuity returned to baseline, and intraocular inflammation rarely recurred with repeat IVB or intravitreal ranibizumab.

Overview

Integrity signals

Registry

Crossref · 10.1097/iae.0b013e3181dc04da

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Cited by

See all 68

Metadata

Authors
Chong, D. Y., Anand, R., Williams, P. D., Qureshi, J. A., & Callanan, D. G.
Affiliations
Texas Retina Associates (United States) (US)
Venue
Retina
Published
2010-10
Volume
30
Issue
9
Pages
1432-1440
ISSN
0275-004X (ISSN-L)
OpenAlex
W2036940508
Cited by
66
References
14
Citations by year
2026: 3 · 2025: 4 · 2024: 2 · 2023: 4 · 2022: 5 · 2021: 6 · 2020: 5 · 2019: 4 · 2018: 1 · 2017: 3 · 2016: 4 · 2015: 6 · 2014: 7 · 2013: 7 · 2012: 4
FWCI
4.20
Type
journal article
Language
en
Open access
closed
Locations
  • Retina (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Ophthalmology › Ocular Diseases and Behçet’s Syndrome
  • Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
  • Health Sciences › Medicine › Ophthalmology › Ocular Infections and Treatments
Keywords
bevacizumab, intravitreal injection, ranibizumab, recurrent inflammation, anti-VEGF therapy, visual acuity recovery
MeSH terms
Bevacizumab, Aged, Antibodies, Monoclonal, Female, Humans, Macular Degeneration, Macular Edema, Male, Endophthalmitis, Postoperative Complications, Retrospective Studies, Time Factors, Visual Acuity, Incidence, Retreatment, Recovery of Function, Angiogenesis Inhibitors, Vascular Endothelial Growth Factor A, Intravitreal Injections, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.